Skip to main content
. 2023 Jul;19(7 Suppl 3):3–4.

Table 1.

The Most Frequent TEAEs for All Patients Who Entered the OLE From TN

All TN Patients Enrolled in the OLE (N=823)
Adverse Event n (%)
TEAEs 672 (81.7)
Serious TEAEs 149 (18.1)
TEAEs leading to treatment discontinuation 55 (6.7)
Most frequent TEAEs (occurring in ≥5% of patients)

  • Lymphopenia

  • Anemia

  • Nasopharyngitis

  • Decreased lymphocyte count

  • Increased alanine aminotransferase

  • Arthralgia

  • COVID-19

  • Headache

  • Upper respiratory tract infection

  • Increased γ-glutamyl transferase

  • Hypertension

  • UC exacerbation

  • Cough

 128 (15.6)
86 (10.4)
85 (10.3)
84 (10.2)
74 (9.0)
74 (9.0)
66 (8.0)
63 (7.7)
56 (6.8)
54 (6.6)
49 (6.0)
44 (5.3)
42 (5.1)

OLE, open-label extension; TEAE, treatment-emergent adverse event; TN, True North; UC, ulcerative colitis. Adapted from Abreu et al. Abstract 950. Presented at: DDW 2023; May 6-9, 2023; Chicago, Illinois.4